Experienced in Mixed Connective Tissue Disease

Dr. Theresa Karplus

Rheumatology
700 Ne 87th Ave, 
Vancouver, WA 
Experienced in Mixed Connective Tissue Disease
700 Ne 87th Ave, 
Vancouver, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Theresa Karplus is a Rheumatologist in Vancouver, Washington. Dr. Karplus is rated as an Experienced provider by MediFind in the treatment of Mixed Connective Tissue Disease. Her top areas of expertise are Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA), Ankylosing Spondylitis, and Rheumatoid Vasculitis.

Her clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

700 Ne 87th Ave, Vancouver, WA 98664

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials
Similar Doctors
Advanced in Mixed Connective Tissue Disease
Dr. Simona S. Braun
Rheumatology
Advanced in Mixed Connective Tissue Disease
Dr. Simona S. Braun
Rheumatology

Providence Health And Services Oregon

1108 June St, 
Hood River, OR 
 (51.6 miles away)
541-387-6125
Languages Spoken:
English, Czech
See accepted insurances
Accepting New Patients

Simona Braun is a Rheumatologist in Hood River, Oregon. Dr. Braun is rated as an Advanced provider by MediFind in the treatment of Mixed Connective Tissue Disease. Her top areas of expertise are Rheumatoid Arthritis (RA), Mixed Connective Tissue Disease, MASS Phenotype, and Necrotizing Vasculitis. Dr. Braun is currently accepting new patients.

Advanced in Mixed Connective Tissue Disease
Dr. Peter P. Bonafede
Rheumatology
Advanced in Mixed Connective Tissue Disease
Dr. Peter P. Bonafede
Rheumatology
5050 Northeast Hoyt Street, Suite 155, 
Portland, OR 
 (6.1 miles away)
503-215-6819
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Peter Bonafede is a Rheumatologist in Portland, Oregon. Dr. Bonafede is rated as a Distinguished provider by MediFind in the treatment of Mixed Connective Tissue Disease. His top areas of expertise are Rheumatoid Pneumoconiosis, Rheumatoid Lung Disease, Ankylosing Spondylitis, and Axial Spondyloarthritis (AxSpA). Dr. Bonafede is currently accepting new patients.

Experienced in Mixed Connective Tissue Disease
Dr. Esther C. Hwang
Rheumatology
Experienced in Mixed Connective Tissue Disease
Dr. Esther C. Hwang
Rheumatology

The Vancouver Clinic Inc Ps

700 Ne 87th Ave, 
Vancouver, WA 
 (0.1 miles away)
360-882-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Esther Hwang is a Rheumatologist in Vancouver, Washington. Dr. Hwang is rated as an Experienced provider by MediFind in the treatment of Mixed Connective Tissue Disease. Her top areas of expertise are Microscopic Polyangiitis, Psoriatic Arthritis, MASS Phenotype, and Mixed Connective Tissue Disease. Dr. Hwang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karplus's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile